Category: Press Release - Page 142 - Psychedelic Alpha

Explore our new Pα+ Psychedelic Bill Tracker.

Read more about the article Novamind Partners with Merck for New Treatment-Resistant Depression Trial

Novamind Partners with Merck for New Treatment-Resistant Depression Trial

Post published:March 18, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

Post published:March 18, 2021
Post category:Press Release

Read more about the article atai Life Sciences AG Announces Equity Investment in and Strategic Partnership with IntelGenx Technologies Corp.

atai Life Sciences AG Announces Equity Investment in and Strategic Partnership with IntelGenx Technologies Corp.

Post published:March 17, 2021
Post category:Press Release

Read more about the article Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

Bright Minds Biosciences Announces Closing of $25.9 Million Unit Offering

Post published:March 17, 2021
Post category:Press Release

Read more about the article Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study

Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study

Post published:March 17, 2021
Post category:Press Release

Read more about the article Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal Financing

Field Trip Health Ltd. Announces Closing of $95 Million Bought Deal Financing

Post published:March 17, 2021
Post category:Press Release

Read more about the article Psyched Wellness Submits a Provisional Patent Application For AME-1

Psyched Wellness Submits a Provisional Patent Application For AME-1

Post published:March 17, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Post published:March 17, 2021
Post category:Press Release

Read more about the article Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch

Optimi Health Receives Health Canada NPN Product Licenses in Preparation for Q2 Sales Launch

Post published:March 16, 2021
Post category:Press Release

Read more about the article World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor

World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor

Post published:March 16, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.